TrialNature communications2022

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).

Jianming Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.